STS subtypea
| Hazard ratio | 95% confidence interval |
|---|
Angiosarcoma | 6.4 | (1.9–21.8)+
|
GIST | 20.9 | (13.6–32.2)+
|
Leiomyosarcoma | 49.3 | (22.2–109.0)+
|
Liposarcoma | 19.1 | (4.2–87.4)+
|
MFHb
| 11.9 | (3.6–39.4)+
|
NSTc
| 15.8 | (5.8–42.7)+
|
Sarcoma NOSd
| 15.4 | (10.9–21.8)+
|
- All models adjusted for age. Recent VTE history = history of VTE in the 12 months before STS diagnosis. VTE venous thromboembolic event, including deep vein thrombosis, pulmonary embolism, and other thromboembolic events. The other thromboembolic event category includes the following diagnoses: central retinal vein occlusion, venous tributary (branch) occlusion, nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, Budd–Chiari syndrome, and venous embolism/thrombosis of renal vein.
-
aHazard ratios for STS subtypes other than those listed were not estimable due to small numbers.
-
bMaligant fibrous histiocytoma.
-
cNerve sheath tumor.
-
dSarcoma not otherwise specified.
-
+Statistically significant.
